drugset / Trial / NCT05109052
Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This trial will assess the safety and tolerability of PXS-5505 incorporating first-line combination therapy Atezolizumab and Bevacizumab in unresectable or metastatic hepatocellular carcinoma. Phase 2 will assess the efficacy of this combination therapy in unresectable or metastatic hepatocellular carcinoma.
Timeline
- Start
- 2022-09-20
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PXS-5505 | Unknown | 100 mg | — |
| Subject | PXS-5505 | Unknown | 200 mg | — |
| Background | Atezolizumab | Monoclonal antibody | 1200 mg | — |
| Background | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |